Skye Bioscience, Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
SKYE$0.84+21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity for the (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · TotalStockholders’Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amounts | ||||||||
| Balance, January 1, 2025 | 30,974,559 | $30,975 | $199,070,421 | $(130,949,672) | $68,151,724 | |||
| Stock-based compensation expense | — | — | 2,201,909 | — | 2,201,909 | |||
| Net loss for the three months ended March 31, 2025 | — | — | — | (11,103,319) | (11,103,319) | |||
| Balance, March 31, 2025 | 30,974,559 | $30,975 | $201,272,330 | $(142,052,991) | $59,250,314 | |||
| Stock-based compensation expense | 3,750 | 4 | 2,033,105 | — | 2,033,109 | |||
| Purchases under employee stock purchase plan | 9,799 | 9 | 18,149 | — | 18,158 | |||
| Net loss for the three months ended June 30, 2025 | — | — | — | (17,624,872) | (17,624,872) | |||
| Balance, June 30, 2025 | 30,988,108 | $30,988 | $203,323,584 | $(159,677,863) | $43,676,709 | |||
| Stock-based compensation expense | 938 | 1 | 1,914,135 | — | 1,914,136 | |||
| Net loss for the three months ended September 30, 2025 | — | — | — | (12,754,660) | (12,754,660) | |||
| Balance, September 30, 2025 | 30,989,046 | $30,989 | $205,237,719 | $(172,432,523) | $32,836,185 | |||
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · TotalStockholders’Equity/(Deficit) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amounts | ||||||||
| Balance, January 1, 2024 | 12,349,243 | $12,349 | $102,238,382 | $(104,382,549) | $(2,131,818) | |||
| Stock-based compensation expense | — | — | 2,478,179 | — | 2,478,179 | |||
| Issuance of common stock and warrants, net of issuance costs of $6,434,447 | 15,713,664 | 15,714 | 83,540,849 | — | 83,556,563 | |||
| Net loss for the three months ended March 31, 2024 | — | — | — | (5,019,531) | (5,019,531) | |||
| Balance, March 31, 2024 | 28,062,907 | $28,063 | $188,257,410 | $(109,402,080) | $78,883,393 | |||
| Stock-based compensation expense | 5,000 | 5 | 1,828,469 | — | 1,828,474 | |||
| Net loss for the three months ended June 30, 2024 | — | — | — | (7,902,816) | (7,902,816) | |||
| Balance, June 30, 2024 | 28,067,907 | $28,068 | $190,085,879 | $(117,304,896) | $72,809,051 | |||
| Stock-based compensation expense | — | — | 1,921,617 | — | 1,921,617 | |||
| Conversion of convertible note - related party | 968,973 | 969 | 4,970,035 | — | 4,971,004 | |||
| Exercise of pre-funded warrants | 1,301,410 | 1,301 | (1,301) | — | — | |||
| Net loss for the three months ended September 30, 2024 | — | — | — | (3,898,297) | (3,898,297) | |||
| Balance, September 30, 2024 | 30,338,290 | $30,338 | $196,976,230 | $(121,203,193) | $75,803,375 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.